BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
66.48
-1.13 (-1.67%)
At close: Feb 27, 2026, 4:00 PM EST
68.00
+1.52 (2.29%)
After-hours: Feb 27, 2026, 7:44 PM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for BridgeBio Pharma stock have an average target of 82.26, with a low estimate of 49 and a high estimate of 125. The average target predicts an increase of 23.74% from the current stock price of 66.48.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock from 23 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 9 | 9 | 9 | 8 | 8 |
| Buy | 9 | 9 | 10 | 12 | 13 | 15 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 18 | 19 | 21 | 21 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $86 → $95 | Strong Buy | Maintains | $86 → $95 | +42.90% | Feb 25, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $83 → $81 | Buy | Maintains | $83 → $81 | +21.84% | Feb 25, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $96 → $98 | Buy | Maintains | $96 → $98 | +47.41% | Feb 25, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $100 → $125 | Buy | Maintains | $100 → $125 | +88.03% | Feb 25, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $90 → $100 | Strong Buy | Maintains | $90 → $100 | +50.42% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
931.60M
from 502.08M
Increased by 85.55%
Revenue Next Year
1.59B
from 931.60M
Increased by 71.10%
EPS This Year
-1.86
from -3.78
EPS Next Year
0.54
from -1.86
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.3B | 1.9B | |||
| Avg | 931.6M | 1.6B | |||
| Low | 739.9M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 159.1% | 102.3% | |||
| Avg | 85.5% | 71.1% | |||
| Low | 47.4% | 24.5% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.71 | 2.63 | |||
| Avg | -1.86 | 0.54 | |||
| Low | -2.79 | -1.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.